具有鼻息肉的慢性鼻炎的生物学因素:耳鼻喉科医生的观点
Michael F Armstrong1, Brent A Senior2
1Department of Otolaryngology-Head and Neck Surgery, University of North Carolina, Chapel Hill, NC, USA.
Current allergy and asthma reports
|January 10, 2026
概括
透视鼻外科手术 (ESS) 与生物药物一样有效,并且比生物药物更具成本效益,用于患有鼻息肉的慢性鼻炎 (CRSwNP). 生物药物可能是严重的CRSwNP病例的选择,这些病例对综合性ESS有抗性.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 免疫学 免疫学 免疫学
- 卫生经济学 卫生经济学
背景情况:
- 带鼻息肉的慢性鼻炎 (CRSwNP) 越来越多地使用生物疗法来治疗.
- 单克隆抗体为CRSwNP提供了一个新的治疗途径.
研究的目的:
- 为了比较生物治疗的疗效和成本效益与CRSwNP的内镜外科手术 (ESS).
- 评估目前关于CRSwNP管理的指导方针.
主要方法:
- 对生物药物和ESS临床试验数据的比较分析.
- 对两种治疗方式的成本效益数据的审查.
- 审查CRSwNP管理的最新欧洲和美国指导方针.
主要成果:
- 透视鼻手术 (ESS) 显示,对CRSwNP的生物药物来说,与生物药物可比的症状控制.
- 对于CRSwNP而言,ESS的成本效益明显高于生物疗法.
- 目前的指导方针支持ESS作为耐火性CRSwNP的主要治疗方法.
结论:
- ESS是一种具有成本效益和有效的CRSwNP治疗.
- 在严重的CRSwNP病例中,可以考虑使用生物药物,这些病例已经失败了全面的ESS.
- 需要进一步研究生物药物与CRSwNP的ESS的长期疗效和成本.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Drugs Used in Upper Respiratory Disorders: Overview
616
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
616
Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
COPD: Management Using Bronchodilators and Corticosteroids
713
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
713
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463


